MXPA04000613A - DERIVADOS DE aCIDO PIRIDINILO Y PIRIMIDILTRIENOICO COMO MODULADORES DE RECEPTOR DE RETINOIDE X. - Google Patents
DERIVADOS DE aCIDO PIRIDINILO Y PIRIMIDILTRIENOICO COMO MODULADORES DE RECEPTOR DE RETINOIDE X.Info
- Publication number
- MXPA04000613A MXPA04000613A MXPA04000613A MXPA04000613A MXPA04000613A MX PA04000613 A MXPA04000613 A MX PA04000613A MX PA04000613 A MXPA04000613 A MX PA04000613A MX PA04000613 A MXPA04000613 A MX PA04000613A MX PA04000613 A MXPA04000613 A MX PA04000613A
- Authority
- MX
- Mexico
- Prior art keywords
- retinoid
- pyrimidyl
- pyridinyl
- compounds
- acid derivatives
- Prior art date
Links
- 102000034527 Retinoid X Receptors Human genes 0.000 title abstract 4
- 108010038912 Retinoid X Receptors Proteins 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title 1
- 125000004076 pyridyl group Chemical group 0.000 title 1
- 125000000714 pyrimidinyl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 229940122355 Insulin sensitizer Drugs 0.000 abstract 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000005495 thyroid hormone Substances 0.000 abstract 1
- 229940036555 thyroid hormone Drugs 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30695101P | 2001-07-20 | 2001-07-20 | |
| PCT/US2002/023017 WO2003007950A1 (en) | 2001-07-20 | 2002-07-18 | (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04000613A true MXPA04000613A (es) | 2004-05-05 |
Family
ID=23187597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04000613A MXPA04000613A (es) | 2001-07-20 | 2002-07-18 | DERIVADOS DE aCIDO PIRIDINILO Y PIRIMIDILTRIENOICO COMO MODULADORES DE RECEPTOR DE RETINOIDE X. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040248913A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1414450A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2005514327A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2002319583B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2452541A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MXPA04000613A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2003007950A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1368296A1 (en) * | 2001-03-14 | 2003-12-10 | Eli Lilly And Company | Fluorinated trienes and their use as rxr modulators |
| ES2687177T3 (es) * | 2010-02-19 | 2018-10-24 | Arizona Board Of Regents, A body corporate of the State of Arizona acting, For and on behalf of Arizona State University | Inhibidores de radicales multifuncionales y su uso |
| CA2976937C (en) | 2015-02-17 | 2023-04-04 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| CA2976776C (en) | 2015-02-17 | 2023-06-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Phenothiazine analogues as mitochondrial therapeutic agents |
| US11390605B2 (en) | 2016-08-25 | 2022-07-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071773A (en) * | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| US4981784A (en) * | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
| US5977125A (en) * | 1994-10-31 | 1999-11-02 | Eisai Co., Ltd. | Mono-or polyenic carboxylic acid derivatives |
| AU726450B2 (en) * | 1995-10-06 | 2000-11-09 | Ligand Pharmaceuticals Incorporated | Dimer-selective RXR modulators and methods for their use |
| US6593493B1 (en) * | 1999-09-14 | 2003-07-15 | Ligand Pharmaceuticals, Inc. | RXR modulators with improved pharmacologic profile |
| EP1368296A1 (en) * | 2001-03-14 | 2003-12-10 | Eli Lilly And Company | Fluorinated trienes and their use as rxr modulators |
-
2002
- 2002-07-18 CA CA002452541A patent/CA2452541A1/en not_active Abandoned
- 2002-07-18 WO PCT/US2002/023017 patent/WO2003007950A1/en not_active Ceased
- 2002-07-18 US US10/483,160 patent/US20040248913A1/en not_active Abandoned
- 2002-07-18 JP JP2003513557A patent/JP2005514327A/ja active Pending
- 2002-07-18 EP EP02750182A patent/EP1414450A1/en not_active Withdrawn
- 2002-07-18 MX MXPA04000613A patent/MXPA04000613A/es not_active Application Discontinuation
- 2002-07-18 AU AU2002319583A patent/AU2002319583B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20040248913A1 (en) | 2004-12-09 |
| AU2002319583B2 (en) | 2005-08-25 |
| CA2452541A1 (en) | 2003-01-30 |
| JP2005514327A (ja) | 2005-05-19 |
| EP1414450A1 (en) | 2004-05-06 |
| WO2003007950A1 (en) | 2003-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004052847A3 (en) | Tricyclic steroid hormone nuclear receptor modulators | |
| WO2002074247A3 (en) | Pharmaceutical formulations for sustained release | |
| MX2021011647A (es) | Moduladores del receptor x4 de proteina g relacionado con mas y productos y metodos relacionados. | |
| MY148637A (en) | Anti-glypican-3 antibody having improved kinetics in plasma | |
| WO2003075835A3 (en) | Compositions and methods for regulating thyroid hormone metabolism and cholesterol and lipid metabolism via the nuclear receptor car | |
| EP2172472A3 (en) | Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| MY142029A (en) | Phenoxyacetic acid derivatives | |
| CA2290622A1 (en) | Selective thyroid hormone analogs | |
| EP1928236A4 (en) | COMPOUNDS AND COMPOSITIONS CONTAINING DIARYLAMINE, AND USE AS MODULATORS OF C-KIT RECEPTORS | |
| DE60039878D1 (de) | XENON ALS NMDA-ANTOGONIST zur Neuroprotektion | |
| WO2022061008A3 (en) | Modulators of mas-related g-protein receptor x4 and related products and methods | |
| IE810315L (en) | Indane derivatives | |
| WO2003063791A3 (en) | Non-steroidal analogs of 2-methoxyestradiol | |
| WO2007022255A3 (en) | Pharmaceutical formulations for sustained release | |
| SE9904413D0 (sv) | Comminuted form | |
| WO2002057215A3 (en) | Sodium channel modulators | |
| AU2001250365A1 (en) | Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients | |
| AU3406799A (en) | S-substituted 11beta-benzaldoxime-estra-4,9-diene-carbonic acid thiolesters, method for the production thereof and pharmaceutical preparations containing these compounds | |
| WO2008048648A3 (en) | Cb1-modulating compounds and their use | |
| WO2003042177A8 (en) | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | |
| WO2005101989A3 (en) | Piperidine derivatives as modulators of chemokine receptor ccr5 | |
| IL183779A0 (en) | Vitamin d receptor modulators | |
| AU1572301A (en) | Cyclopentyl sulfonamide derivatives | |
| MX2010003594A (es) | Formas cristalinas de sal sodica de dmxaa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |